Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biomarker Identifies Sarcopenia Patients with Excessive Neurotrypsin Activity

By LabMedica International staff writers
Posted on 07 Mar 2012
A novel biomarker was developed to identify the subgroup of patients (40%), whose sarcopenia is caused by excessive neurotrypsin activity. More...


The biomarker developed by Neurotune (Zurich, Switzerland), is the 22 kDa C-terminal agrin fragment (CAF). When agrin is inactivated by neurotrypsin, CAF is released and can be detected in the blood. Elevated levels of CAF are indicative of increased neurotrypsin activity and a measure of reduced neuromuscular junctions (NMJs) strength. The NTCAF enzyme-linked immunosorbent assay (ELISA) detects CAF in human serum.

Neurotrypsin regulates the strength of communication between nerve and muscle cells by cleaving and inactivating agrin. Excessive neurotrypsin activity causes deterioration of the synapses and subsequently muscle atrophy.

CAF is detectable in serum in healthy adults, aged between 20-75 years, defining a normal range. Approximately 40% of sarcopenia patients show statistically significant increased CAF levels above normal.

NTCAF ELISA was developed by Neurotune in collaboration with MicroCoat Biotechnologie GmbH (Bernried am Starnberger See, Germany), and the Eureka-Eurostars program (Brussels, Belgium). It is available immediately from Neurotune.

Neurotune is continuing to develop the ELISA assay as a marker of dysfunction of the neurotrypsin/agrin system in other pathological conditions.

Sarcopenia is a debilitating muscle disorder frequently affecting the elderly for which there is currently no cure. It is defined as loss of skeletal muscle mass and strength that occurs with advancing age. The current diagnosis of the disease is by dual-emission X-ray absorptiometry (DXA) scan, which measures lean body mass (LBM) in combination with functional tests. This cumbersome technique does not provide information on the underlying cause of loss of LBM.

It is estimated that sarcopenia currently affects over 50 million people worldwide and with the aging population this is expected to increase to over 200 million in the next 40 years.

Neurotune develops medications to treat disorders of the human nervous system. MicroCoat Biotechnologie is active in the field of immune and nucleic acid diagnostics. The purpose of the Eurostars Program is to provide funding for market-oriented research and development by small and medium-sized enterprises.

Related Links:

Neurotune
MicroCoat Biotechnologie GmbH
Eureka-Eurostars program




Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.